公开(公告)号：US20220111043A1

公开(公告)日：2022-04-14

申请号：US17277906

申请日：2019-09-19

Applicant: LAVA THERAPEUTICS B.V.

Inventor： Johannes Jelle VAN DER VLIET ,  Roeland LAMERIS ,  Tanja Denise DE GRUIJL ,  Paul Willem Henri Ida PARREN

IPC: A61K39/395 ,  A61P35/00

Abstract: The present invention relates to the field of immunology, more in particular to the field of binding moieties and/or immunoglobulins which bind to human CD1d, including antibodies and fragments thereof that modify CD1d-mediated biological functions such as enhanced activation and reduced activation of CD1d-restricted T cells, including the natural killer T-cells and gamma-delta T-cells, and modulation of the function of cells expressing CD1d. The invention also relates to bi-, tri- or multi-specific immunoglobulins that bind to CD1d and a gamma-delta TCR and/or a tumor target. The invention further relates to pharmaceutical preparations and use of such mono-, bi-, and tri- or multi-specific binding moieties and/or immunoglobulins in the treatment of diseases or disorders.

公开(公告)号：US20220135694A1

公开(公告)日：2022-05-05

申请号：US17427291

申请日：2020-01-30

Applicant: LAVA THERAPEUTICS B.V.

Inventor： Johannes Jelle VAN DER VLIET ,  Iris DE WEERDT ,  Tanja Denise DE GRUIJL ,  Paul PARREN ,  Aron Philip KATER ,  George Lodewijk SCHEFFER

IPC: C07K16/28 ,  A61P35/00

Abstract: The present invention relates to novel antibodies capable of binding human CD40 and to novel multispecific antibodies capable of binding human CD40 and capable of binding a human Vγ9Vδ2 T cell receptor. The invention further relates to pharmaceutical compositions comprising the antibodies of the invention and to uses of the antibodies of the invention for medical treatment.

公开(公告)号：US20180142020A1

公开(公告)日：2018-05-24

申请号：US15546406

申请日：2016-01-27

Applicant: LAVA THERAPEUTICS B.V.

Inventor： Johannes Jelle VAN DER VLIET ,  Tanja Denise DE GRUIJL ,  Hendrik Marinus Willem VERHEUL ,  Renée Cornelia Gerarda DE BRUIN ,  Roeland LAMERIS

IPC: C07K16/28 ,  C07K16/30

CPC classification number: C07K16/2809 ,  C07K16/2833 ,  C07K16/30 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/75

Abstract: The invention relates to compounds, in particular polypeptides that specifically bind to the non-classical MHC protein CD1d and modulate CD1d-mediated biological functions. The invention in particular relates to such compounds and polypeptides comprising or consisting of at least one single domain antibody, and wherein at least one single domain antibody specifically binds to CD1d. Also provided is for methods and use employing such compounds, polypeptides and/or single-domain antibodies.

公开(公告)号：US20210371525A1

公开(公告)日：2021-12-02

申请号：US17277984

申请日：2019-09-19

Applicant: LAVA THERAPEUTICS B.V.

Inventor： Iris DE WEERDT ,  Arnon Philip KATER ,  Paul Willem Henri Ida PARREN ,  Tanja Denise DE GRUIJL ,  Johannes Jelle VAN DER VLIET ,  Roeland LAMERIS

IPC: C07K16/28 ,  A61P35/02

Abstract: The present invention relates to novel methods for the treatment of hematological malignancies. In particular, the invention relates to the treatment of hematological malignancies using antibodies comprising a first binding moiety that is able to bind human CD1d and a second binding moiety that is able to bind the human Vγ9Vδ2-TCR.